• search
For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

COVID-19 vaccine: Oxford, Pfizer or Moderna, which is better

|

New Delhi, Nov 23: The phase 3 interim analysis of the Oxford/AstraZeneca Covid-19 vaccine candidate has shown as 70.4 per cent efficacy in preventing the disease. In two different dosing regiments, the vaccine AZD1222, showed the efficacy of 90 per cent and 62 per cent.

    Oxford Covid vaccine upto 90% effective, what are the advantages to this vaccine|Oneindia News

    "Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine," a statement from AstraZeneca read.

    COVID-19 vaccine: Oxford, Pfizer or Moderna, which is better

    In the dosing regimen with higher efficacy AZD1222 was given as a half dose followed by a fill dose one month apart.

    25,000 health workers identified in Meghalaya for first batch of coronavirus vaccine

    Another dosing regimen showed lower efficacy when given as two full doses at least one month apart. The combined analysis from both regimens resulted in an average efficacy of 70 per cent.

    Now let us take a look at the vaccines developed by Pfizer and Modern, which have a 95 per cent efficacy. While the efficacy is higher, the AZD1222 can be stored at fridge temperature, while the other two need much colder temperature.

    Pfizer's vaccine candidate needs to be stored at minus 75°C and can be kept in the fridge for five days. Moderna's vaccine candidate mRNA-1273 is expected to remain stable at standard refrigerated conditions of 2°C to 8°C for up to 30 days within the 6-month shelf life.

    Oxford-AstraZeneca Covid-19 vaccine found to be highly effective

    In terms of pricing Oxford's vaccine candidate scores better as it costs a fraction of what Pfizer and Moderna are charing. Oxford's vaccine candidate will be manufactured iii India and Brazil and on Thursday, Adar Poonawalla of Serum Institute of India said that the vaccine will be priced at Rs 500-600.

    For Daily Alerts
    Get Instant News Updates
    Enable
    x
    Notification Settings X
    Time Settings
    Done
    Clear Notification X
    Do you want to clear all the notifications from your inbox?
    Settings X
    X